Method: We report a case of a 55-year old man with spinal granulocytic sarcoma manifesting as rapidly progressive paraplegia preceding clinical manifestation of acute myeloid leukemia. Results: Magnetic resonance imaging revealed a tumor in lumbal spine (L1-L3). Baseline laboratory data were normal. He underwent emergent laminectomy and the tumor was totaly resected. Histological examination of lesion demonstrated diffuse proliferation of large atypical cells with round nuclei with delicate chromatin and one or more prominent nucleoli. Immunohistochemical studies revealed positive staining for LCA, CD33, CD43, CD163, Lysozyme and CD15 while myeloperoxidase, lymphoid, neuroendocrine markers, S-100 and CD99 were negative. The final histological diagnosis was granulocitic (monoblastic) sarcoma. No chromosomal aberrations were detected by FISH. A month later, acute myelomonocytic leukemia was diagnosed upon a peripheral blood and bone marrow examination showing an increased number of abnormal monoblasts. Chemotherapy, with multiple regimens for leukemia in combination, did not affect the tumor and the patient died. Conclusion: Granulocytic sarcoma should be considered in the differential diagnosis of spinal tumors. Objective: Survivin, a member of the inhibitor of apoptosis family might play an important role in the pathogenesis of diffuse large B cell lymphoma (DLBCL). We investigate clinical and prognostic significance of survivin expression in nodal DLBCL. Method: Biopsy specimens obtained from 56 patients with newly diagnosed nodal DLBCL treated with immunochemotherapy (R-CHOP) were immunostained for survivin. Results: Survivin immunoexpression (>45 % positive tumor cells) has been found in 22 (39.28 %) patients. Significant difference in immunoexpression was noticed between GCB and non-GCB subtype of DLBCL (p=0.031). There was no significant association with IPI, "bulky"disease, Ki-67 immunoexpression or other clinico-pathological parameters. Univariate analysis showed that survivin expression was unfavorable factor for therapy response and shorter survival in patients with DLBCL (p=0.048 and p=0.034, respectively). Patients with survivin overexpression experienced relapse more often that the patients without expression of this apoptotic protein (27.3 % vs. 11.8 %), but this difference did not reach statistical significance (p=0.131).